Vitamin D deficiency contributes to spread of breast cancer in mice – Stanford Medical Center Report

A brake on tumor progression?

The link between vitamin D and calcium metabolism is well-known. More recently, however, researchers have begun to suspect that vitamin D may affect many other important biological processes, including tumor progression. However, it’s not clear exactly which step in cancer development the vitamin may affect.

In the new study, Williams and Aggarwal investigated whether vitamin D levels affected the metastatic ability of mouse breast cancer cells implanted into the mammary fat pad of laboratory mice. One group of 10 mice was first fed a diet lacking in the vitamin for 10 weeks; the other 10 received a normal dose in their food. 

Mice fed a diet deficient in vitamin D developed palpable tumors an average of seven days sooner than their peers, and after six weeks of growth those tumors were significantly larger in size than those in animals with adequate vitamin D levels. 

The researchers then examined two well-characterized lines of mouse tumor cells, 168FARN and 4T1. Prior research has shown that cells from either group form tumors when implanted in laboratory mice, but only 4T1 results in aggressive tumors that spread to other parts of the animal’s body. 

Vitamin D and ID1 expression

The researchers found that the 4T1 cell line expresses significantly lower levels of the vitamin D receptor protein. When they genetically engineered 168FARN cells to also have lower-than-normal levels of the VDR protein, the cells began to behave much more like the 4T1 cells. They migrated more freely in a laboratory dish and, when injected into 10 mice, they grew aggressively. In six of these mice, the modified cancer cells metastasized to the liver during the course of four weeks. In contrast, none of the tumors in the 10 mice that received unmodified 168FARN cells spread to the liver during the study period.

To identify how vitamin D might be affecting metastasis, the researchers analyzed gene expression in the tumors that developed in mice with varied levels of vitamin D in their diets and in the tumors of mice injected with modified or unmodified 168FARN cells. They found that in cases in which vitamin D was lacking from the diet or in which cells were missing much of the VDR protein, tumor cells expressed more of a gene called ID1, which has been shown to play a role in breast cancer metastasis. Further investigation showed that VDR binds directly to a stretch of DNA near the ID1 gene and suppresses its expression in both mouse and human cells. 

Finally, the researchers compared circulating vitamin D levels in 34 breast cancer patients at Stanford with the levels of ID1 in tumor cells that were surgically removed during the course of disease treatment. They found an inverse correlation: Women with lower levels of vitamin D expressed more ID1 in their tumor tissues than did women with higher levels of vitamin D. 

“Our study shows that a deficiency in vitamin D levels, or an inability of tumor cells to respond appropriately to the presence of vitamin D, is sufficient to trigger non-metastatic cancer cells to become metastatic,” said Feldman. “It’s enough to significantly accelerate tumor progression in our mouse model. Further studies are warranted, but this direct association between vitamin D levels and ID1 expression is very interesting to us.” 

Other Stanford co-authors of the paper are research associate Srilatha Swami, PhD, senior research scientist Aruna Krishnan, PhD, postdoctoral scholar Lijuan Ji, PhD, and assistant professor of comparative medicine Megan Albertelli, PhD. 

The research was supported by the Stanford Cancer Institute, the California Breast Cancer Research Program and a National Institutes of Health Director’s New Innovator Award. 

Stanford’s Department of Pediatrics also supported the work.


Write a Reply or Comment:

Your email address will not be published.*